106
Participants
Start Date
November 5, 2021
Primary Completion Date
February 28, 2025
Study Completion Date
May 31, 2025
NDI-101150
NDI-101150 capsules
Pembrolizumab
Pembrolizumab IV infusion
Columbia University Irving Medical Center, New York
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
NEXT Oncology, Fairfax
Ocala Oncology Center, Ocala
Norton Cancer Institute, Louisville
Henry Ford Cancer, Detroit
University of Wisconsin, Madison
HealthPartners Cancer Research Center, Saint Paul
Washington University, St Louis
Stephenson Cancer Center, Oklahoma City
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Center for Oncology and Blood Disorders, Houston
Oncology Consultants, Houston
NEXT Oncology, San Antonio
Honor Health Research Institute, Scottsdale
Northwest Medical Specialties, Tacoma
Yale Cancer Center, New Haven
Georgetown University, Washington D.C.
Hackensack University, Hackensack
Nimbus Saturn, Inc.
INDUSTRY